Search Results
Optimizing the Use of Anti-BCMA Therapy in MM
The Role of Anti-BCMA Therapies
Symposium | BCMA-directed ADCs for the treatment of MM
How to optimize access to CAR-T cell therapies in multiple myeloma
Best Practices for the Myeloma Care Team: Optimizing Outcomes for Patients With R/R Multiple Myeloma
Anti-BCMA CAR T-cells for MM: durable clinical responses with ide-cel (formerly bb2121)
The management & optimization of CAR T-cell therapy in myeloma
Novel strategies to optimize CAR-T therapy in myeloma
Anti-BCMA CAR T-cell therapy for multiple myeloma: latest studies
When is the optimal time to use bispecific antibodies in MM?
Bispecific BCMA-CD3 antibody teclistamab is efficacious and tolerable in R/R MM
Optimizing the outcomes of autoHSCT in multiple myeloma
